| Date | Title | Description |
| 20.02.2026 | Curt Smith: Fighting blood cancer is easier with a group effort | - |
| 24.11.2025 | ToolGen and GenEditBio Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics | Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technology
Pursues a "once-and-done" treatment paradigm for diseases with high unmet medical needs
SEOUL,... |
| 24.11.2025 | GenEditBio and ToolGen Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics | Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technology
Pursues a "once-and-done" treatment paradigm for diseases with high unmet medical needs
SEOUL,... |
| 18.06.2025 | Indexes end lower as Israel-Iran fighting raises investor anxiety | Indexes end lower as Israel-Iran fighting raises investor anxiety
By Caroline ValetkevitchJune 17, 20259:07 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
FILE PHOTO; Traders work on the floor ... |
| 17.06.2025 | Stocks making the biggest moves midday: Jabil, JetBlue, Sunrun, Valero, Verve Therapeutics and more | - |
| 17.06.2025 | Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why | - |
| 19.12.2022 | How a gene-editing breakthrough from a Harvard lab saved the life of a girl with leukemia | Alyssa, 13, was the first patient to receive a base-edited cell therapy to treat her leukemia in May 2022. Great Ormond Street Hospital for Children
A 13-year-old girl was the world's first patient to get a cell therapy called base editing ... |
| 12.10.2022 | Gene-editing companies are growing thanks to fast-paced science, even as biotech faces a downturn | Marianne Ayala/Insider This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Redeem now
A handful of biotechs specializing in gene editing are charging ahead despite an industry downturn.
Inste... |
| 10.05.2022 | Verve gets New Zealand clearance to test base editing therapy directly in the human body | Two years ago, Intellia and Editas Medicine ventured into the field of science fiction when the biotechs directly edited genes in humans.
Now, following behind those two companies, which have reported limited data th... |
| 10.11.2021 | Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2021 Financial Results | VERVE-101 Preclinical Data Announced at TIDES 2021 Demonstrated Potent, Durable PCSK9 Protein and LDL-C Reductions, Supporting Planned Clinical Initiation in 2022
New Preclinical Data from ANGPTL3 Program Highlight Potent Editing with Propr... |
| 14.06.2021 | Verve Therapeutics Prepares $201 Million IPO | - |
| 28.05.2021 | Gene editing biotech Verve Therapeutics files for a $100 million IPO | - |
| 01.02.2021 | Gene Editing Medicine Company Verve Therapeutics Raises $94 Million | Verve Therapeutics — a biotech company pioneering gene-editing medicines to treat cardiovascular disease — recently announced it has raised $94 million in Series B funding. These are the details.
Verve Therapeutics — a biotech company pione... |
| 19.01.2021 | Verve Therapeutics Closes $94 Million Series B | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verve Therapeutics, a biotech company pioneering gene editing medicines to treat cardiovascular disease, today announced the successful completion of a $94 million Series B financing, led by Wellington Man... |
| 19.01.2021 | Verve Therapeutics Secures $94 Million in Series B Financing to Advance Pipeline of Gene Editing Medicines for Cardiovascular Disease | - |
| 19.01.2021 | Verve Therapeutics Secures $94M in Series B Financing | Verve Therapeutics, a Cambridge, Mass.-based biotech company pioneering gene editing medicines to treat cardiovascular disease, closed a $94m Series B financing.
The round was led by Wellington Management Company and co-led by Casdin Capita... |
| 15.06.2020 | Gene-editing company raises €56M in Series A2 to advance gene-editing therapies for curing heart disease | Gene editing is a type of genetic engineering and it is a relatively newer concept. It involves insertion, deletion, modification or replacement of DNA in a living organism’s genome. Gene editing could be a powerful tool for helping people ... |
| 12.06.2020 | Gene-Editing Company Verve Therapeutics Secures $63 Million | Verve Therapeutics, a next-generation cardiovascular company developing therapies, announced it raised $63 million
Verve Therapeutics — a next-generation cardiovascular company developing therapies that safely edit the adult human genome to... |
| 11.06.2020 | Verve banks $63M to move gene-editing heart attack treatment toward clinic | Verve Therapeutics launched last year with $58.5 million to create a one-and-done treatment to replace the array of drugs we use to treat heart disease. Now, it’s gearing up to move its first program into the clinic, and it’s snagged anothe... |
| 11.06.2020 | Verve Therapeutics : Raises $63 million in Series A2 Financing to Advance Gene-Editing Therapies for Heart Disease | Verve Therapeutics, a next-generation cardiovascular company developing therapies that safely edit the adult human genome to permanently reduce a person’s risk of coronary heart disease, today announced it has raised $63 million in a Series... |
| 11.06.2020 | Verve banks $63M to move gene-editing heart attack treatment toward clinic | Verve Therapeutics launched last year with $58.5 million to create a one-and-done treatment to replace the array of drugs we use to treat heart disease. Now, it’s gearing up to move its first program into the clinic, and it’s snagged anothe... |
| 11.06.2020 | Verve Therapeutics Raises $63 million in Series A2 | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verve Therapeutics, a next-generation cardiovascular company developing therapies that safely edit the adult human genome to permanently reduce a person’s risk of coronary heart disease, today announced it... |
| 08.05.2019 | Term Sheet — Wednesday, May 8 | THE $1 BILLION LOSS
2019 will be Lyft’s “peak loss year.” The ride-hailing giant has issued its first results as a public company, showing both strong growth and widening losses.
Paid Content How can you protect what you can't see? From Ext... |
| 07.05.2019 | Verve Therapeutics Launches with $58.5M in Series A Funding | Verve Therapeutics, a Cambridge, Mass.-based next-generation cardiovascular company, has launched with $58.5m in Series A funding.
The round was led by GV (formerly Google Ventures), with participation from ARCH Venture Partners, F-Prime Ca... |
| 07.05.2019 | Verve Therapeutics Raises $58.5M in Series A Funding Led by GV | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verve Therapeutics, a next-generation cardiovascular company, today announced its launch to discover and develop therapies that safely edit the adult human genome to permanently reduce a person’s risk of c... |
| 07.05.2019 | Verve Therapeutics Lands $58.5M Series A |
CAMBRIDGE, MA, Verve Therapeutics, a next-generation cardiovascular company, has raised $58.5 million in Series A funding.
>> Click here for more funding data on Verve Therapeutics
>> To export Verve Therapeutics funding dat... |
| 07.05.2019 | Verve Therapeutics Founded to Protect Against Heart Disease Launches with $58.5 Million in Series A Funding Led by GV | - |
| - | Under pressure, biotech and pharma grapple with how to take climate action | As the health impacts of climate change become harder to ignore, biotechnology and pharmaceutical companies are facing increasing pressure from investors, employees, and government regulators to reduce their carbon emissions, and to make en... |
